ANNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Annexon Inc (ANNX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signs, the lack of significant positive catalysts, weak financial performance, and absence of strong trading signals suggest that it is better to hold off on investing in this stock right now.
The MACD is positive and contracting, indicating mild bullish momentum. The RSI is neutral at 53.192, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 5.263. However, the price has declined by 2.86% in the regular market and 0.55% in post-market trading, suggesting short-term weakness.
Analyst Daniil Gataulin from Chardan has initiated a Buy rating with a $16 price target, citing the commercial potential of the company's complement C1q inhibitors in multiple indications. This could indicate long-term growth potential.
No significant news or recent trading trends from hedge funds or insiders. The financial performance remains weak with no revenue, significant net losses, and negative EPS despite YoY improvements. The stock has a low chance of significant short-term gains based on historical patterns.
In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of $54.92M (improved by 57.71% YoY), and an EPS of -0.37 (up 48% YoY). While losses are narrowing, the financials remain weak overall.
Chardan analyst initiated a Buy rating with a $16 price target, citing the potential of the company's pipeline in Guillain-Barre syndrome, geographic atrophy, and Huntington's disease. This indicates optimism for long-term growth but lacks immediate impact.
